Tuesday 01 December 2020

US-based clinical trial management technology provider Signant Health has acquired VirTrial, a provider of software solutions for remote site startup and decentralized clinical trial conduct, the company said.

Signant Health said that, by adding the capabilities of VirTrial, the company now expands its software stack to further digitally enhance trial sites and offer sponsors superior evidence generation across traditional, decentralized, and hybrid trial models.

Signant Health's suite of technology and clinical expertise, combined with VirTrial's telemedicine platform, will better support sites as sponsors accelerate their trial strategies toward digital methods during COVID-19 and beyond.

In addition to VirTrial's tele-research platform, which includes secure video, audio, chat, and connected medical device capabilities for decentralized patient-site interaction and assessments, the agreement provides Signant with a revolutionary solution to address remote site startup and monitoring.

Known as Virtual Site Monitoring, the solution leverages wearable technology for in-house or outsourced clinical research associates to remotely conduct site evaluation, initiation, and monitoring visits.

VirTrial's platform enables pharmaceutical companies and CROs to empower their preferred clinical research sites to perform virtual visits a combination of secure video, audio, chat and messaging, which can be used on any device.

Incorporating VirTrial's virtual visits into study protocols opens the door to a wider participant pool, ultimately yielding improved study outcomes and efficient site performance.

Unlike other clinical trial vendors that began as technology companies, VirTrial has a stable of clinical research veterans and experienced tech entrepreneurs teaming together to lead the company towards providing the human population with remote access to clinical research sites.